Obsessive-compulsive disorder (OCD) is a chronic and debilitating neuropsychiatric disorder characterized by recurrent obsessions and compulsions that significantly impair quality of life and daily functioning. Although cognitive behavioural therapy (CBT) and pharmacotherapy remain the mainstay of treatment, many patients experience incomplete response, relapse, or adverse effects associated with long-term therapy. Consequently, increasing attention has been directed toward herbal medicines and phytochemicals as potential alternative or adjunctive therapeutic approaches for OCD.
This review summarizes the available evidence regarding herbal medicines and phytoconstituents investigated for OCD, with emphasis on their therapeutic potential, proposed mechanisms of action, and findings from preclinical and clinical studies.
Relevant articles were retrieved from PubMed, Scopus, Web of Science, Open Access Journals, and Google Scholar up to 31st December 2025 using keywords including “obsessive-compulsive disorder”, “OCD”, “medicinal plants”, “herbal medicine”, and “phytomedicine”.
Clinical studies, particularly randomized controlled trials, suggest that Crocus sativus, Withania somnifera, Valeriana officinalis, and Echium amoenum may reduce OCD symptom severity, primarily assessed using Yale-Brown Obsessive Compulsive Scale (Y-BOCS) scores. Preclinical studies further demonstrated anti-obsessive effects of several medicinal plants through modulation of serotonergic, dopaminergic, and glutamatergic pathways, along with antioxidant, anti-inflammatory, and neuroprotective activities. However, the current evidence remains limited by small sample sizes, short follow-up duration, lack of replication studies, and methodological heterogeneity involving variations in herbal preparations, dosages, and study designs. In addition, mechanisms related to immune regulation, neuroinflammation, oxidative stress, and gut–brain interactions remain insufficiently explored.
Herbal medicines demonstrate promising therapeutic potential in OCD management; however, the existing clinical evidence remains insufficient to support routine clinical use. Future research should prioritize large double-blind randomized controlled trials with standardized herbal formulations, longer follow-up periods, and comprehensive safety evaluation, along with mechanistic studies investigating immune, inflammatory, and gut–brain pathways involved in OCD pathophysiology.
Citation: Anjali Saini, Sarita Khatkar, Priyanka Rathee, Neelam Malik, Sunil Sharma, Anurag Khatkar. Herbal medicines in obsessive-compulsive disorder: Pre-clinical and clinical evidence[J]. AIMS Molecular Science, 2026, 13(3): 367-392. doi: 10.3934/molsci.2026017
Obsessive-compulsive disorder (OCD) is a chronic and debilitating neuropsychiatric disorder characterized by recurrent obsessions and compulsions that significantly impair quality of life and daily functioning. Although cognitive behavioural therapy (CBT) and pharmacotherapy remain the mainstay of treatment, many patients experience incomplete response, relapse, or adverse effects associated with long-term therapy. Consequently, increasing attention has been directed toward herbal medicines and phytochemicals as potential alternative or adjunctive therapeutic approaches for OCD.
This review summarizes the available evidence regarding herbal medicines and phytoconstituents investigated for OCD, with emphasis on their therapeutic potential, proposed mechanisms of action, and findings from preclinical and clinical studies.
Relevant articles were retrieved from PubMed, Scopus, Web of Science, Open Access Journals, and Google Scholar up to 31st December 2025 using keywords including “obsessive-compulsive disorder”, “OCD”, “medicinal plants”, “herbal medicine”, and “phytomedicine”.
Clinical studies, particularly randomized controlled trials, suggest that Crocus sativus, Withania somnifera, Valeriana officinalis, and Echium amoenum may reduce OCD symptom severity, primarily assessed using Yale-Brown Obsessive Compulsive Scale (Y-BOCS) scores. Preclinical studies further demonstrated anti-obsessive effects of several medicinal plants through modulation of serotonergic, dopaminergic, and glutamatergic pathways, along with antioxidant, anti-inflammatory, and neuroprotective activities. However, the current evidence remains limited by small sample sizes, short follow-up duration, lack of replication studies, and methodological heterogeneity involving variations in herbal preparations, dosages, and study designs. In addition, mechanisms related to immune regulation, neuroinflammation, oxidative stress, and gut–brain interactions remain insufficiently explored.
Herbal medicines demonstrate promising therapeutic potential in OCD management; however, the existing clinical evidence remains insufficient to support routine clinical use. Future research should prioritize large double-blind randomized controlled trials with standardized herbal formulations, longer follow-up periods, and comprehensive safety evaluation, along with mechanistic studies investigating immune, inflammatory, and gut–brain pathways involved in OCD pathophysiology.
| [1] |
Kawahito M, Murayama K, Tomiyama H, et al. (2025) Diversity of group cognitive behavioral therapy for obsessive-compulsive disorder: A scoping review protocol. JBI Evid Synth 23: 1687-1694. https://doi.org/10.11124/JBIES-24-00380 
|
| [2] | Lee EB (2025) Acceptance and commitment therapy for obsessive-compulsive disorder. Psych Clin 48: 457-466. |
| [3] |
Zisler E, Meule A, Endres D, et al. (2024) Effects of inpatient, residential, and day-patient treatment on obsessive–compulsive symptoms in persons with obsessive–compulsive disorder: A systematic review and meta-analysis. J Psychiatr Res 176: 182-197. https://doi.org/10.1016/j.jpsychires.2024.06.007
|
| [4] |
Bloch MH, Artukoglu BB, Lennington JB, et al. (2020) Obsessive–compulsive disorder. In: Rosenberg's molecular and genetic basis of neurological and psychiatric. Academic Press 663-674. https://doi.org/10.1016/B978-0-12-813866-3.00039-4
|
| [5] |
de Souza AMFLP, Mpavaenda D, Banca P, et al. (2026) Habit as a therapeutic component in psychological treatment for obsessive-compulsive disorder: A randomised controlled feasibility study. Compr Psychiatr 146: 152666. https://doi.org/10.1016/j.comppsych.2026.152666
|
| [6] |
Coenen VA, Polosan M, Schlapfer TE, et al. (2025) Deconstructing a common pathway concept for Deep Brain Stimulation in the case of obsessive-compulsive disorder. Mol Psychiatr 30: 4274-4285. https://doi.org/10.1038/s41380-025-03008-x
|
| [7] |
Kalanthroff E, Berebbi S, David M, et al. (2025) Acute trauma and obsessive compulsive disorder: Evidence from October 7th, 2023. Psychother Psychosom 95: 105-116. https://doi.org/10.1159/000548026
|
| [8] |
Linde ES, Varga TV, Clotworthy V, et al. (2022) Obsessive-compulsive disorder during the COVID-19 pandemic—A systematic review. Front Psychiatry 13: 806872. https://doi.org/10.3389/fpsyt.2022.806872
|
| [9] |
Pozza A, Ragucci F, Angelo NL, et al. (2024) Worldwide prevalence of obsessive-compulsive symptoms during the COVID-19 pandemic: A systematic review and meta-analysis. J Psychiatr Res 172: 360-381. https://doi.org/10.1016/j.jpsychires.2024.02.031
|
| [10] |
Pampaloni I, Marriott S, Pessina E, et al. (2022) The global assessment of OCD. Compr Psychiat 118: 152342. https://doi.org/10.1016/j.comppsych.2022.152342
|
| [11] |
Shitova DA, Zharikova TS, Kovaleva ON, et al. (2023) Tourette syndrome and obsessive-compulsive disorder: A comprehensive review of structural alterations and neurological mechanisms. Behav Brain Res 453: 114606. https://doi.org/10.1016/j.bbr.2023.114606
|
| [12] |
Boone L, Shafie M, Naeem, A, et al. (2026) Neuroimaging in lesioning therapy for obsessive-compulsive disorder: Region-based and network analysis of preoperative outcome predictors and postoperative effects. NeuroImage-Clin 49: 103976. https://doi.org/10.1016/j.nicl.2026.103976
|
| [13] |
Goodman WK, Storch EA, Sheth SA (2021) Harmonizing the neurobiology and treatment of obsessive-compulsive disorder. Am J Psychiatry 178: 17-29. https://doi.org/10.1176/appi.ajp.2020.20111601
|
| [14] |
Pittenger C (2026) Biological mechanisms and treatment of obsessive–compulsive disorder. Annu Rev Clini Psychol 22: 455-480. https://doi.org/10.1146/annurev-clinpsy-081423-020516
|
| [15] | Xu X, Li Z, Wan S, et al. (2025) The role of immune-inflammatory factors in the pathophysiology of obsessive–compulsive disorder. PsychoNeuroImmunology . Springer 247-261. https://doi.org/10.1007/978-3-031-72079-6_10 |
| [16] |
Ding Z, Ding Z, Chen Y, et al. (2023) Decreased gray matter volume and dynamic functional alterations in medicine-free obsessive-compulsive disorder. BMC psychiatry 23: 289. https://doi.org/10.1186/s12888-023-04740-w
|
| [17] |
de Oliveira CT, Dias ACG (2023) How can psychoeducation help in the treatment of mental disorders. Estudos de Psicologia 40: e190183.
|
| [18] | Shofty B, Gadot R, Provenza N, et al. (2023) Neurosurgical approaches for treatment-resistant obsessive-compulsive disorder. Psychiat Clin 46: 121-132. |
| [19] |
Steele DW, Kanaan G, Caputo EL, et al. (2025) Treatment of obsessive-compulsive disorder in children and youth: A meta-analysis. Pediatrics 155: e2024068992. https://doi.org/10.1542/peds.2024-068992
|
| [20] |
Conti D, Girone N, Boscacci M, et al. (2024) The use of antipsychotics in obsessive compulsive disorder. Hum Psychopharm Clin 39: e2893. https://doi.org/10.1002/hup.2893
|
| [21] |
Wang Y, Miguel C, Ciharova M, et al. (2025) Effectiveness and acceptability of cognitive–behavioural therapy delivery formats for obsessive–compulsive disorder: Network meta-analysis. Br J Psychiatry 228: 252-262. https://doi.org/10.1192/bjp.2024.197
|
| [22] |
Burk BG, DiGiacomo T, Polancich S, et al. (2023) Antipsychotics and obsessive–compulsive disorder/obsessive–compulsive symptoms: A pharmacovigilance study of the FDA adverse event reporting system. Acta Psychiat Scand 148: 32-46. https://doi.org/10.1111/acps.13567
|
| [23] | Yazdi-Ravandi S, Taslimi Z, Khosrowabadi R, et al. (2026) Neurofeedback as an adjunct to pharmacotherapy in OCD: A randomized controlled trial on symptom reduction. Appl Psycholphysiol Biofeedback . https://doi.org/10.1007/s10484-025-09758-2 |
| [24] |
Reid JE, Laws KR, Drummond L, et al. (2021) Cognitive behavioural therapy with exposure and response prevention in the treatment of obsessive-compulsive disorder: A systematic review and meta-analysis of randomised controlled trials. Compr Psychiat 106: 152223. https://doi.org/10.1016/j.comppsych.2021.152223
|
| [25] |
van Roessel PJ, Grassi G, Aboujaoude EN, et al. (2023) Treatment-resistant OCD: Pharmacotherapies in adults. Compr Psychiat 120: 152352. https://doi.org/10.1016/j.comppsych.2022.152352
|
| [26] |
Abrishami MH, Noras MR, Soltanifar A, et al. (2022) Clinical evidence for the effectiveness of herbal medicines in the treatment of an obsessive-compulsive disorder: A review study. Curr Drug Discov Technol 19: e160622206086. https://doi.org/10.2174/1570163819666220616122543
|
| [27] |
Pitre V, Shrivastava S, Shrivastava M (2026) Obsessive–Compulsive disorder and the role of nutrition. Nourishing the brain . Singapore: Springer 275-287. https://doi.org/10.1007/978-981-95-4169-0_11
|
| [28] |
van Wyk AS, Prinsloo G (2020) Health, safety and quality concerns of plant-based traditional medicines and herbal remedies. S Afr J Bot 133: 54-62. https://doi.org/10.1016/j.sajb.2020.06.031
|
| [29] |
Scangos KW, State MW, Miller AH, et al. (2023) New and emerging approaches to treat psychiatric disorders. Nat Med 29: 317-333. https://doi.org/10.1038/s41591-022-02197-0
|
| [30] |
Khan I, Jaura TA, Tukruna A, et al. (2023) Use of selective alternative therapies for treatment of OCD. Neuropsych Dis Treat 2023: 721-732. https://doi.org/10.2147/NDT.S403997
|
| [31] |
Kalariya M, Prajapati R, Parmar S, et al. (2015) Effect of hydroalcoholic extract of leaves of Colocasia esculenta on marble-burying behavior in mice: implications for obsessive–compulsive disorder. Pharm Biol 53: 1239-1242. https://doi.org/10.3109/13880209.2015.1014923
|
| [32] |
Kalariya M, Parmar S, Sheth N (2010) Neuropharmacological activity of hydroalcoholic extract of leaves of Colocasia esculenta. Pharm Biol 48: 1207-1212. https://doi.org/10.3109/13880201003586887
|
| [33] | Zhang LM, Yao JZ, Li Y, et al. (2012) Anxiolytic effects of flavonoids in animal models of posttraumatic stress disorder. Evid-Based Compl Alte 53: 623753. https://doi.org/10.1155/2012/623753 |
| [34] | Oliveira AI, Pinho C, Sarmento B, et al. (2016) Neuroprotective activity of Hypericum perforatum and its major components. Front Plant Sci 7: 1004. https://doi.org/10.3389/fpls.2016.01004 |
| [35] |
Yue QY, Bergquist C, Gerdén B (2000) Safety of St John's wort (Hypericum perforatum). Lancet 355: 576-577. https://doi.org/10.1016/S0140-6736(05)73227-X
|
| [36] |
Booker A, Agapouda A, Frommenwiler DA, et al. (2018) St John's wort (Hypericum perforatum) products–an assessment of their authenticity and quality. Phytomedicin 40: 158-164. https://doi.org/10.1016/j.phymed.2017.12.012
|
| [37] |
Butterweck V (2003) Mechanism of action of St John's wort in depression: What is known?. CNS drugs 17: 539-562. https://doi.org/10.2165/00023210-200317080-00001
|
| [38] |
Di Carlo G, Borrelli F, Ernst E, et al. (2001) St John's wort: Prozac from the plant kingdom. Trends Pharmacol Sci 22: 292-297. https://doi.org/10.1016/S0165-6147(00)01716-8
|
| [39] |
Erdelmeier CAJ, Koch E, Hoerr R (2000) Hypericum perforatum-St. John's Wort chemical, pharmacological and clinical aspects. Stud Nat Prod Chem 22: 643-716. https://doi.org/10.1016/S1572-5995(00)80037-X
|
| [40] | Hypericum Depression Trial Study Group.Effect of Hypericum perforatum (St John's Wort) in major depressive disorder: A randomized controlled trial. JAMA (2002) 287: 1807-1814. https://doi.org/10.1186/s13643-016-0325-2 |
| [41] |
Russo E, Scicchitano F, Whalley BJ, et al. (2014) Hypericum perforatum: Pharmacokinetic, mechanism of action, tolerability, and clinical drug-drug interactions. Phytother Res 28: 643-655. https://doi.org/10.1002/ptr.5050
|
| [42] |
Kobak KA, Taylor LVH, Bystritsky A, et al. (2005) St John's wort versus placebo in obsessive–compulsive disorder: results from a double-blind study. Int Clini Psychopharm 20: 299-304. https://doi.org/10.1097/00004850-200511000-00003
|
| [43] |
Kobak KA, Taylor LVH (2000) An open-label trial of St. John's Wort (Hypericum perforatum) in obsessive-compulsive disorder. J Clin Psychiatry 61: 575-578. https://doi.org/10.4088/jcp.v61n0806
|
| [44] |
Prajapati RP, Kalaria MV, Karkare VP, et al. (2011) Effect of methanolic extract of Lagenaria siceraria (Molina) Standley fruits on marble-burying behavior in mice: Implications for obsessive–compulsive disorder. Pharmacogn Res 3: 62. https://doi.org/10.4103/0974-8490.79118
|
| [45] |
Ghule BV, Ghante MH, Saoji AN, et al. (2009) Antihyperlipidemic effect of the methanolic extract from Lagenaria siceraria Stand. fruit in hyperlipidemic rats. J Ethnopharmacol 124: 333-337. https://doi.org/10.1016/j.jep.2009.04.040
|
| [46] |
Saeed M, Khan MS, Amir K, et al. (2022) Lagenaria siceraria fruit: A review of its phytochemistry, pharmacology, and promising traditional uses. Front Nutr 9: 927361. https://doi.org/10.3389/fnut.2022.927361
|
| [47] |
Arjun VN, Ramchandra NM, Mahesh NS, et al. (2025) Comprehensive review on Lagenaria siceraria: medicinal potential and nutritional significance. J Med Plant Stud 13: 140-146. https://doi.org/10.22271/plants.2025.v13.i3b.1856
|
| [48] | Al-Snafi AE (2013) The pharmacological importance of Benincasa hispida. A review. Int J Pharm Sci Res 4: 165-170. |
| [49] |
Atiwetin P, Harada S, Kamei K (2006) Serine proteinase inhibitor from wax gourd (Benincasa hispida [Thunb] Cogn.) seeds. Biosci Biotech Biochem 70: 743-745. https://doi.org/10.1271/bbb.70.743
|
| [50] | Girdhar S, Wanjari MM, Prajapati SK, et al. (2010) Evaluation of anti-compulsive effect of methanolic extract of Benincasa hispida Cogn. fruit in mice. Acta Pol Pharm 67: 417v421. |
| [51] |
Grover JK, Adiga G, Vats V, et al. (2001) Extracts of Benincasa hispida prevent development of experimental ulcers. J Ethnopharm 78: 159-164. https://doi.org/10.1016/S0378-8741(01)00334-8
|
| [52] | Nimbal SK, Venkatrao N, Ladde S, et al. (2011) Anxiolytic evaluation of Benincasa hispida (Thunb) Cogn. fruit extracts. Int Res J Pharm 1: 93-97. |
| [53] | Nimbal SK, Venkatrao N, Pujar B, et al. (2011) Evaluation of anticonvulsant activity of alcoholic extract of Benincasa hispida (Thunb) Cogn. fruit extracts. Int Res J Pharm 2: 166-168. https://doi.org/10.53730/ijhs.v6nS6.9704 |
| [54] |
Jenkins TA, Nguyen JCD, Polglaze KE, et al. (2016) Influence of tryptophan and serotonin on mood and cognition with a possible role of the gut-brain axis. Nutrients 8: 56. https://doi.org/10.3390/nu8010056
|
| [55] |
Kaurav BPS, Wanjari MM, Chandekar A, et al. (2012) Influence of Withania somnifera on obsessive compulsive disorder in mice. Asian Pac J Trop Med 5: 380-384. https://doi.org/10.1016/S1995-7645(12)60063-7
|
| [56] |
Bhattacharya SK, Bhattacharya A, Sairam K, et al. (2000) Anxiolytic-antidepressant activity of Withania somnifera glycowithanolides: An experimental study. Phytomedicine 7: 463-469. https://doi.org/10.1016/S0944-7113(00)80030-6
|
| [57] |
Davis L, Kuttan G (2000) Immunomodulatory activity of Withania somnifera. J Ethnopharmacol 71: 193-200. https://doi.org/10.1016/S0378-8741(99)00206-8
|
| [58] |
Dar NJ, Ahmad M (2020) Neurodegenerative diseases and Withania somnifera (L.): An update. J Ethnopharmacol 256: 112769. https://doi.org/10.1016/j.jep.2020.112769
|
| [59] |
Talaei A, Forouzanfar F, Akhondzadeh S (2021) Medicinal plants in the treatment of obsessive-compulsive disorder: A review. Curr Drug Discov Technol 18: 8-16. https://doi.org/10.2174/1570163816666191011105050
|
| [60] |
Jahanbakhsh SP, Manteghi AA, Emami SA, et al. (2016) Evaluation of the efficacy of Withania somnifera (Ashwagandha) root extract in patients with obsessive-compulsive disorder: A randomized double-blind placebo-controlled trial. Complement Ther Med 27: 25-29. https://doi.org/10.1016/j.ctim.2016.03.018
|
| [61] | Pratchayasakul W, Pongchaidecha A, Chattipakorn N, et al. (2008) Ethnobotany & ethnopharmacology of Tabernaemontana divaricata. Indian J Med Res 127: 317-335. |
| [62] | Thombre R, Jagtap R, Patil N (2013) Evaluation of phytoconstituents, antibacterial, antioxidant and cytotoxic activity of Vitex negundo L. and Tabernaemontana divaricata L. Int J Pharm Bio Sci 4: 389-396. |
| [63] | Chanchal R, Balasubramaniam A, Navin R, et al. (2015) Tabernaemontana divaricata leaves extract exacerbate burying behavior in mice. Avicenna J Phytomed 5: 282-287. |
| [64] |
Mukherjee PK, Kumar V, Kumar NS, et al. (2008) The Ayurvedic medicine Clitoria ternatea—From traditional use to scientific assessment. J Ethnopharmacol 120: 291-301. https://doi.org/10.1016/j.jep.2008.09.009
|
| [65] | Boominathan R, Devi BP, Mandal SC (2003) Studies on neuropharmacological effects of Clitoria ternatea Linn. root extract in rats and mice. Nat Prod Sci 9: 260-263. |
| [66] | Al-Snafi AE (2016) Pharmacological importance of Clitoria ternatea–A review. IOSR J Pharm 6: 68-83. |
| [67] |
Jain NN, Ohal CC, Shroff SK, et al. (2003) Clitoria ternatea and the CNS. Pharmacol Biochem Be 75: 529-536. https://doi.org/10.1016/S0091-3057(03)00130-8
|
| [68] | Shende V, Sahane R, Lawar M, et al. (2012) Evaluation of anti-compulsive effect of ethanolic extract of Clitoria ternatea in mice. Asian J Pharm Clin Res 5: 120-123. |
| [69] |
Stohs JJ (2017) Safety, efficacy, and mechanistic studies regarding Citrus aurantium (bitter orange) extract and p-synephrine. Phytother Res 31: 1463-1474. https://doi.org/10.1002/ptr.5879
|
| [70] |
Leite MP, Fassin J, Baziloni EMF, et al. (2008) Behavioral effects of essential oil of Citrus aurantium L. inhalation in rats. Rev Bras Farmacogn 18: 661-666. https://doi.org/10.1590/S0102-695X2008000500003
|
| [71] |
Mohamed A, Kouhila M, Jamali A, et al. (2005) Moisture sorption isotherms and heat of sorption of bitter orange leaves (Citrus aurantium). J Food Eng 67: 491-498. https://doi.org/10.1016/j.jfoodeng.2004.05.016
|
| [72] |
Rahnama S, Rabiei Z, Alibabaei Z, et al. (2015) Anti-amnesic activity of Citrus aurantium flowers extract against scopolamine-induced memory impairments in rats. Neurol Sci 36: 553-560. https://doi.org/10.1007/s10072-014-1991-2
|
| [73] |
Carvalho-Freitas MIR, Costa M (2002) Anxiolytic and sedative effects of extracts and essential oil from Citrus aurantium L. Biol Pharm Bull 25: 1629-1233. https://doi.org/10.1248/bpb.25.1629
|
| [74] |
de Moraes Pultrini A, Galindo LA, Costa M (2006) Effects of the essential oil from Citrus aurantium L. in experimental anxiety models in mice. Life Sci 78: 1720-1725. https://doi.org/10.1016/j.lfs.2005.08.004
|
| [75] |
Samarghandian S, Azimi-Nezhad M, Borji A, et al. (2016) Effect of crocin on aged rat kidney through inhibition of oxidative stress and proinflammatory state. Phytother Res 30: 1345-1353. https://doi.org/10.1002/ptr.5638
|
| [76] |
Samarghandian S, Azimi-Nezhad, Farkhondeh T, et al. (2016) Crocin attenuate Tumor Necrosis Factor-alpha (TNF-α) and interleukin-6 (IL-6) in streptozotocin-induced diabetic rat aorta. Cytokine 88: 20-28. https://doi.org/10.1016/j.cyto.2016.08.002
|
| [77] |
Abdullaev FI (2002) Cancer chemopreventive and tumoricidal properties of saffron (Crocus sativus L.). Exp Bio Med 227: 20-25. https://doi.org/10.1177/153537020222700104
|
| [78] |
Srivastava R, Ahmed H, Dixit RK, et al. (2010) Crocus sativus L.: A comprehensive review. Pharmacogn Rev 4: 200. https://doi.org/10.4103/0973-7847.70919
|
| [79] |
Pitsikas N, Boultadakis A, Georgiadou G, et al. (2008) Effects of the active constituents of Crocus sativus L., crocins, in an animal model of anxiety. Phytomedicine 15: 1135-1139. https://doi.org/10.1016/j.phymed.2008.06.005
|
| [80] |
Graf M, Kantor S, Anheuer ZE, et al. (2003) m-CPP-induced self-grooming is mediated by 5-HT2C receptors. Behav Brain Res 142: 175-179. https://doi.org/10.1016/S0166-4328(02)00404-7
|
| [81] |
Georgiadou G, Tarantilis PA, Pitsikas N (2012) Effects of the active constituents of Crocus Sativus L., crocins, in an animal model of obsessive–compulsive disorder. Neurosci Lett 528: 27-30. https://doi.org/10.1016/j.neulet.2012.08.081
|
| [82] |
Strimpakos AS, Sharma RA (2008) Curcumin: preventive and therapeutic properties in laboratory studies and clinical trials. Antioxid Redox Signal 10: 511-546. https://doi.org/10.1089/ars.2007.1769
|
| [83] |
Soleimani V, Sahebkar A, Hosseinzadeh H (2018) Turmeric (Curcuma longa) and its major constituent (curcumin) as nontoxic and safe substances: Review. Phytother Res 32: 985-995. https://doi.org/10.1002/ptr.6054
|
| [84] |
Momtazi AA, Derosa G, Maffioli P, et al. (2016) Role of microRNAs in the therapeutic effects of curcumin in non-cancer diseases. Mol Diagn Ther 20: 335-345. https://doi.org/10.1007/s40291-016-0202-7
|
| [85] |
Mollazadeh H, Cicero AFG, Blesso CN, et al. (2019) Immune modulation by curcumin: The role of interleukin-10. Crit Rev Food Sci Nutr 59: 89-101. https://doi.org/10.1080/10408398.2017.1358139
|
| [86] |
Panahi Y, Ahmadi Y, Teymouri M, et al. (2018) Curcumin as a potential candidate for treating hyperlipidemia: A review of cellular and metabolic mechanisms. J Cell Physiol 233: 141-152. https://doi.org/10.1002/jcp.25756
|
| [87] |
Ghandadi M, Sahebkar A (2017) Curcumin: An effective inhibitor of interleukin-6. Curr Pharm Design 23: 921-931. https://doi.org/10.2174/1381612822666161006151605
|
| [88] |
Reddy ACP, Lokesh BR (1994) Studies on the inhibitory effects of curcumin and eugenol on the formation of reactive oxygen species and the oxidation of ferrous iron. Mol Cell Biochem 137: 1-8. https://doi.org/10.1007/BF00926033
|
| [89] |
Sreejayan, Rao MNA (1994) Curcuminoids as potent inhibitors of lipid peroxidation. J Pharm Pharmacol 46: 1013-1016. https://doi.org/10.1111/j.2042-7158.1994.tb03258.x
|
| [90] | Chimakurthy J, Murthy TE (2010) Effect of curcumin on quinpirole induced compulsive checking: An approach to determine the predictive and construct validity of the model. North American J Med Sci 2: 2. |
| [91] |
Pertwee RG (2008) The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: Δ9-tetrahydrocannabinol, cannabidiol and Δ9-tetrahydrocannabivarin. Brit J Pharmacol 153: 199-215. https://doi.org/10.1038/sj.bjp.0707442
|
| [92] |
Devinsky O, Jones NA, Cunningham MO, et al. (2024) Cannabinoid treatments in epilepsy and seizure disorders. Physiol Rev 104: 591-649. https://doi.org/10.1152/physrev.00049.202
|
| [93] |
Iuvone T, Esposito G, De Filippis D, et al. (2009) Cannabidiol: A promising drug for neurodegenerative disorders. CNS Neurosci Ther 15: 65-75. https://doi.org/10.1111/j.1755-5949.2008.00065.x
|
| [94] |
Deiana S, Watanabe A, Yamasaki Y, et al. (2012) Plasma and brain pharmacokinetic profile of cannabidiol (CBD), cannabidivarine (CBDV), Δ9-tetrahydrocannabivarin (THCV) and cannabigerol (CBG) in rats and mice following oral and intraperitoneal administration and CBD action on obsessive–compulsive behaviour. Psychopharmacology 219: 859-873. https://doi.org/10.1007/s00213-011-2415-0
|
| [95] | Ranjbar A, Khorami S, Safarabadi M, et al. (2006) Antioxidant activity of Iranian Echium amoenum Fisch & CA Mey flower decoction in humans: a cross-sectional before/after clinical trial. eCAM 3: 469-473. https://doi.org/10.1093/ecam/nel031 |
| [96] |
Abolhassani M (2004) Antibacterial effect of borage (Echium amoenum) on Staphylococcus aureus. Braz J Infect Dis 8: 382-385. https://doi.org/10.1590/S1413-86702004000500008
|
| [97] | Shafaghi B, Naderi N, Tahmasb L, et al. (2002) Anxiolytic effect of Echium amoenum L. in mice. Iranian J Pharm Res 1: 37-41. |
| [98] |
Sayyah M, Boostani H, Pakseresht S, et al. (2009) Efficacy of aqueous extract of Echium amoenum in treatment of obsessive–compulsive disorder. Prog Neuro-Psychoph 33: 1513-1516. https://doi.org/10.1016/j.pnpbp.2009.08.021
|
| [99] |
Ball KR, Kowdley KV (2005) A review of Silybum marianum (milk thistle) as a treatment for alcoholic liver disease. J Clin Gastroenterol 39: 520-528. https://doi.org/10.1097/01.mcg.0000165668.79530.a0
|
| [100] |
Sayyah M, Boostani H, Pakseresht S, et al. (2010) Comparison of Silybum marianum (L.) Gaertn. with fluoxetine in the treatment of obsessive–compulsive disorder. Prog Neuro-Psychoph 34: 362-365. https://doi.org/10.1016/j.pnpbp.2009.12.016
|
| [101] |
Shaker E, Mahmoud H, Mnaa S (2004) Silymarin, the antioxidant component and Silybum marianum extracts prevent liver damage. Food Chem Toxicol 48: 803-806. https://doi.org/10.1016/j.fct.2009.12.011
|
| [102] |
Fernández S, Wasowski C, Paladini AC, et al. (2004) Sedative and sleep-enhancing properties of linarin, a flavonoid-isolated from Valeriana officinalis. Pharmacol Biochem Be 77: 399-404. https://doi.org/10.1016/j.pbb.2003.12.003
|
| [103] |
Murphy K, Kubin ZJ, Shepherd JN, et al. (2010) Valeriana officinalis root extracts have potent anxiolytic effects in laboratory rats. Phytomedicine 17: 674-678. https://doi.org/10.1016/j.phymed.2009.10.020
|
| [104] |
Houghton PJ (1999) The scientific basis for the reputed activity of Valerian. J Pharm Pharmacol 51: 505-512. https://doi.org/10.1211/0022357991772772
|
| [105] |
Kennedy DO, Wightman EL (2011) Herbal extracts and phytochemicals: plant secondary metabolites and the enhancement of human brain function. Adv Nutr 2: 32-50. https://doi.org/10.3945/an.110.000117
|
| [106] |
Müller CE, Schumacher B, Brattström A, et al. (2002) Interactions of valerian extracts and a fixed valerian–hop extract combination with adenosine receptors. Life Sci 71: 1939-1949. https://doi.org/10.1016/S0024-3205(02)01964-1
|
| [107] |
Sudati JH, Fachinetto R, Pereira RP, et al. (2009) In vitro antioxidant activity of Valeriana officinalis against different neurotoxic agents. Neurochem Res 34: 1372-1379. https://doi.org/10.1007/s11064-009-9917-8
|
| [108] |
Pakseresht S, Boostani H, Sayyah M (2011) Extract of valerian root (Valeriana officinalis L.) vs. placebo in treatment of obsessive-compulsive disorder: a randomized double-blind study. J Complement Integr Med 8: 20121003. https://doi.org/10.2202/1553-3840.1465
|
| [109] | Keerthy S, Joshi KH (2019) The pharmacological importance of Colocasia esculenta Linn: A review. J Pharmacogno Phytochem 8: 1945-1948. |
| [110] |
Skalisz LL, Beijamini V, Andreatini R (2004) Effect of Hypericum perforatum on marble-burying by mice. Phytother Res 18: 399-402. https://doi.org/10.1002/ptr.1450
|
| [111] |
Suryawanshi MV, Gujarathi PP, Mulla T, et al. (2024) Hypericum perforatum: A comprehensive review on pharmacognosy, preclinical studies, putative molecular mechanism, and clinical studies in neurodegenerative diseases. Naunyn-Schmiedeberg's Arch Pharmacol 397: 3803-3818. https://doi.org/10.1007/s00210-023-02915-6
|
| [112] | Ibrahim M, Hammoudi M (2020) Phytochemistry and pharmacological activity of pear (Pyrus communis Linn): A review. Plant Arch 20: 7820-7828. |
| [113] |
Chimakurthy J, Murthy TEGK, Diwan PV (2019) Relationship between dopamine and serotonin on the effect of ginkgo biloba extract in the treatment of obsessive-compulsive disorder in rodents. Indian J Pharm Sci 81: 431-437. https://doi.org/10.36468/pharmaceutical-sciences.527
|
| [114] |
More MP, Motule AS, Dongare PN, et al. (2021) Pharmacognosy, phytochemistry, pharmacology and clinical application of Ginkgo biloba. GSC Biol Pharm Sci 16: 229-240. https://doi.org/10.30574/gscbps.2021.16.2.0249
|
| [115] |
Ayati Z, Sarris J, Chang D, et al. (2020) Herbal medicines and phytochemicals for obsessive–compulsive disorder. Phytother Res 34: 1889-1901. https://doi.org/10.1002/ptr.6656
|
| [116] |
Mytych W, Aebisher D (2022) Valeriana officinalis–A review. Eur J Clin Exp Med 3: 260-265. https://doi.org/10.15584/ejcem.2022.3.2
|
| [117] | Lissemore JI, Booij L, Leyton M, et al. (2021) Neuroimaging of obsessive-compulsive disorder: Insights into serotonergic mechanisms. PET and SPECT in psychiatry . Springer 457-478. https://doi.org/10.1007/978-3-030-57231-0_13 |
| [118] |
Yin L, Han F, Wang Q (2023) A biophysical model for dopamine modulating working memory through reward system in obsessive–compulsive disorder. Cogn Neurodyn 18: 1895-1911. https://doi.org/10.1007/s11571-023-09999-z
|
| [119] |
Wang J, Hua G, Wang S, et al. (2023) Glutamatergic neurotransmission is affected by low-frequency repetitive transcranial magnetic stimulation over the supplemental motor cortex of patients with obsessive-compulsive disorder. J Affect Disorders 325: 762-769. https://doi.org/10.1016/j.jad.2023.01.064
|
| [120] |
Kanova M, Kohout P (2021) Serotonin—Its synthesis and roles in the healthy and the critically Ill. Int J Mol Sci 22: 4837. https://doi.org/10.3390/ijms22094837
|
| [121] | Dubey A, Ghosh NS, Agnihotri N, et al. (2022) Herbs derived bioactive compounds and their potential for the treatment of neurological disorders. Clin Schizophr Relat Psychoses 16: 2. https://doi.org/10.3371/CSRP.DANG.081922 |
| [122] |
Goodman WK, Price LH, Rasmussen SA, et al. (1989) The Yale-brown obsessive compulsive scale: II. Validity. Arch Gen Psychiatry 46: 1012-1016. https://doi.org/10.1001/archpsyc.1989.01810110054008
|
| [123] |
Jahanbakhsh G, Haji seyed javadi SA, Majidi M (2023) Effectiveness of adjunctive low-frequency repetitive transcranial magnetic stimulation therapy over the left dorsolateral prefrontal cortex in patients with obsessive-compulsive disorder refractory to medical treatment: A double-blind, randomized clinical trial. Asian J Psychiatry 80: 103384. https://doi.org/10.1016/j.ajp.2022.103384
|
| [124] |
Joel D (2006) Current animal models of obsessive compulsive disorder: A critical review. Prog Neuro Psychiatry 30: 374-388. https://doi.org/10.1016/j.pnpbp.2005.11.006
|
| [125] |
Dixit PV, Sahu R, Mishra DK (2020) Marble-burying behavior test as a murine model of compulsive-like behaviour. J Pharmacol Tox Met 102: 106676. https://doi.org/10.1016/j.vascn.2020.106676
|
| [126] |
Chamberlain BL, Ahmari SE (2021) Animal models for OCD research. The neurobiology and treatment of OCD: Accelerating progress . Switzerland: Springer 55-96. https://doi.org/10.1007/7854_2020_196
|
| [127] |
Tizabi Y, Louis A, Taylor CT, et al. (2002) Effect of nicotine on quinpirole-induced checking behavior in rats: implications for obsessive-compulsive disorder. Biol Psychiatry 51: 164-171. https://doi.org/10.1016/S0006-3223(01)01207-0
|
| [128] | Nimburkar TA, Wankhade AM, Wanjari MM (2018) Evaluation of anti-compulsive effect of ethanolic extract of Bacopa monnieri L. leaves in mice. Indo Am J Pharm Res 8: 14049-14014. https://doi.org/10.5281/zenodo.2530000 |
| [129] | Chinnala KM, Swetha J, Elsani MM (2015) Effects of ethanolic leaf extract of Psidium guajava Linn. on L-arginine induced obsessive compulsive disorder in mice. Sch Acad J Pharm 4: 157-163. |
| [130] | Kumar N, Kumar R, Maheshwari KK (2013) Effect of ethanolic and aqueous extract of Centella asiatica on marble-burying behaviour in mice. Int J Phytopharm 4: 166-170. |
| [131] |
Biswas D, Mandal S, Saha SC, et al. (2021) Ethnobotany, phytochemistry, pharmacology, and toxicity of Centella asiatica (L.) Urban: A comprehensive review. Phytother Res 35: 6624-6654. https://doi.org/10.1002/ptr.7248
|
| [132] |
Casarotto PC, Gomes FV, Resstel LBM, et al. (2010) Cannabidiol inhibitory effect on marble-burying behaviour: involvement of CB1 receptors. Behav Pharmacol 21: 353-358. https://doi.org/10.1097/FBP.0b013e32833b33c5
|
| [133] |
Gawali NB, Chowdhury AA, Kothavade PS, et al. (2016) Involvement of nitric oxide in anticompulsive-like effect of agmatine on marble-burying behaviour in mice. Eur J Pharmacol 770: 165-171. https://doi.org/10.1016/j.ejphar.2015.11.044
|
| [134] | Mesripour A, Payandekhah F (2021) The noradrenergic system is partly involved in resveratrol antidepressant and anti-obsessive like effects in mice model. Res J Pharmacogn 8: 67-75. https://doi.org/10.22127/RJP.2021.277101.1686 |
| [135] | Esalatmanesh S, Biuseh M, Noorbala AA, et al. (2017) Comparison of saffron and fluvoxamine in the treatment of mild to moderate obsessive-compulsive disorder: A double blind randomized clinical trial. Iran J Psychiatry 12: 154-162. |
| [136] |
Grant JE, Odlaug BL (2015) Silymarin treatment of obsessive-compulsive spectrum disorders. J. Clin Psychopharm 35: 340-342. https://doi.org/10.1097/JCP.0000000000000327
|
| [137] |
Pascual-Vera B, Belloch A (2022) Dysmorphic and illness anxiety-related unwanted intrusive thoughts in individuals with obsessive–compulsive disorder. Clin Psychol Psychot 29: 313-327. https://doi.org/10.1002/cpp.2636
|
| [138] | Chougule PR (2025) Shaping the future of chronic diseases: A phyto-mediated natural approach. Medicinal plants and their nanoparticles . Springer 355-390. https://doi.org/10.1007/978-3-032-03604-9_15 |
| [139] |
Alambayan J, Garg V (2020) Overview on phyto-based treatment for anxiety. Current Psychopharmacol 9: 185-210. https://doi.org/10.2174/2211556009999200723122833
|
| [140] | Kiran NS, Yashaswini C, Lowkesh G, et al. (2024) Phytochemicals and herbal medicines: Potential drug candidates for obsessive-compulsive disorder treatment. Nutrition and obsessive-compulsive disorder . New York: CRC Press. |
| [141] |
Bagade S, Patil DD, Shirkhedkar A (2022) Standardization of herbal bioactives. Herbal bioactive-based drug delivery systems: Challenges and opportunities . New York: Academic Press 393-407. https://doi.org/10.1016/B978-0-12-824385-5.00005-4
|
| [142] |
Bhor SD, Chaudhari VS, Lade SN, et al. (2025) Novel therapeutic strategies for neuropsychiatric treatments: Targeted and controlled drug delivery approaches. Biomed Mater Devices 4: 2882-2910. https://doi.org/10.1007/s44174-025-00428-9
|
| [143] |
Pires PC, Paiva-Santos AC, Veiga F (2022) Nano and microemulsions for the treatment of depressive and anxiety disorders: An efficient approach to improve solubility, brain bioavailability and therapeutic efficacy. Pharmaceutics 14: 2825. https://doi.org/10.3390/pharmaceutics14122825
|
| [144] |
Zorkina Y, Abramova O, Ushakova V, et al. (2020) Nano carrier drug delivery systems for the treatment of neuropsychiatric disorders: Advantages and limitations. Molecules 25: 5294. https://doi.org/10.3390/molecules25225294
|
| [145] |
Yadav N, Singh S, Venkatachalam T, et al. (2024) Herbal medicine formulation, standardization, and commercialization challenges and sustainable strategies for improvement. Herbal medicine phytochemistry . Springer 1769-1795. https://doi.org/10.1007/978-3-031-43199-9_40
|
| [146] |
Saggar S, Mir PA, Kumar N, et al. (2022) Traditional and herbal medicines: Opportunities and challenges. Pharmacogn Res 14: 107-114. https://doi.org/10.5530/pres.14.2.15
|
| [147] |
Chandran H, Meena M, Barupal T, et al. (2020) Plant tissue culture as a perpetual source for production of industrially important bioactive compounds. Biotechnol Rep 26: e00450. https://doi.org/10.1016/j.btre.2020.e00450
|
| [148] |
Ozyigit II, Dogan I, Hocaoglu-Ozyigit A, et al. (2023) Production of secondary metabolites using tissue culture-based biotechnological applications. Front Plant Sci 14: 1132555. https://doi.org/10.3389/fpls.2023.1132555
|
| [149] |
Kupeli EK, Çankaya IT, Karatoprak GŞ, et al. (2021) Natural compounds as medical strategies in the prevention and treatment of psychiatric disorders seen in neurological diseases. Front Pharmacol 12: 669638. https://doi.org/10.3389/fphar.2021.669638
|
| [150] |
Jorrin Novo jV (2021) Proteomics and plant biology: contributions to date and a look towards the next decade. Expert Rev Proteomics 18: 93-103. https://doi.org/10.1080/14789450.2021.1910028
|
Figures(3) / Tables(2)
Anjali Saini, Sarita Khatkar, Priyanka Rathee, Neelam Malik, Sunil Sharma, Anurag Khatkar. Herbal medicines in obsessive-compulsive disorder: Pre-clinical and clinical evidence[J]. AIMS Molecular Science, 2026, 13(3): 367-392. doi: 10.3934/molsci.2026017
DownLoad: